Endothelin Antagonism in Pulmonary Arterial Hypertension

ABSTRACT

The pathobiology of pulmonary arterial hypertension (PAH) reflects a multifactorial process and complex evolution that involves dysfunction of underlying cellular pathways and mediators. Among these, the endothelin system has been shown to be important in the pathogenesis of PAH. Endothelin-1 (ET-1), which is found in high levels in PAH, is a known potent vasoconstrictor with proliferative vascular remodeling properties. Left unchecked, endothelin excess, along with other derangements, may contribute to the development and perpetuation of PAH. There is now substantial evidence from clinical trials and long-term data that monotherapy with an endothelin receptor antagonist (ERA) is a beneficial, therapeutic approach in PAH. Combination therapy of an ERA with a prostanoid or phosphodiesterase-5 inhibitor, two drug classes that have different mechanisms of action, is conceptually appealing, but the evidence for its efficacy and safety are still being investigated. This review provides an overview of endothelin biology and the clinical use of ERAs for the treatment of PAH. The use of ERAs for other forms of pulmonary hypertension will not be reviewed here.

KEYWORDS

Pulmonary hypertension - endothelin - bosentan - sitaxsentan

REFERENCES

• 1 Hickey K A, Rubanyi G, Paul R J et al.. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells.  Am J Physiol. 1985;  248 C550-C556
• 2 Yanagisawa M, Kurihara H, Kimura S et al.. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.  Nature. 1988;  332 411-415
• 3 Masaki T, Kimura S, Yanagisawa M et al.. Molecular and cellular mechanism of endothelin regulation: implications for vascular function.  Circulation. 1991;  84 1457-1468
• 4 Wagner O F, Christ G, Wojta J et al.. Polar secretion of endothelin-1 by cultured endothelial cells.  J Biol Chem. 1992;  267 16066-16068
• 5 Davie N, Haleen S J, Upton P D et al.. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. 2002 165: 398-405
• 6 Chua B H, Krebs C J, Chua C C et al.. Endothelin stimulates protein synthesis in smooth muscle cells.  Am J Physiol. 1992;  262 E412-E416
• 7 Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension.  Cardiovasc Res. 2004;  61 227-237
• 8 Williams Jr D L, Jones K L, Colton C D et al.. Identification of high affinity endothelin-1 receptor subtypes in human tissues.  Biochem Biophys Res Commun. 1991;  180 475-480
• 9 Iwamuro Y, Miwa S, Zhang X F et al.. Activation of three types of voltage-independent Ca2+ channel in A7r5 cells by endothelin-1 as revealed by a novel Ca2+ channel blocker LOE 908.  Br J Pharmacol. 1999;  126 1107-1114
• 10 Miwa S, Iwamuro Y, Zhang X F et al.. Ca2+ entry channels in rat thoracic aortic smooth muscle cells activated by endothelin-1.  Jpn J Pharmacol. 1999;  80 281-288
• 11 Takuwa Y, Kasuya Y, Takuwa N et al.. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells.  J Clin Invest. 1990;  85 653-658
• 12 Seo B, Oemar B S, Siebenmann R et al.. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.  Circulation. 1994;  89 1203-1208
• 13 Pollock D M, Keith T L, Highsmith R F. Endothelin receptors and calcium signaling.  FASEB J. 1995;  9 1196-1204
• 14 McCulloch K M, MacLean M R. EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat.  J Cardiovasc Pharmacol. 1995;  26(Suppl 3) S169-S176
• 15 McCulloch K M, Docherty C, MacLean M R. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat.  Br J Pharmacol. 1998;  123 1621-1630
• 16 MacLean M R, McCulloch K M, Baird M. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C and on inherent tone in rat pulmonary arteries.  J Cardiovasc Pharmacol. 1995;  26 822-830
• 17 Dupuis J, Jasmin J F, Prie S et al.. Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone.  Pulm Pharmacol Ther. 2000;  13 135-140
• 18 Hirata Y, Emori T, Eguchi S et al.. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.  J Clin Invest. 1993;  91 1367-1373
• 19 de Nucci G, Gryglewski R J, Warner T D et al.. Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled.  Proc Natl Acad Sci USA. 1988;  85 2334-2338
• 20 Dupuis J, Goresky C A, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors.  J Appl Physiol. 1996;  81 1510-1515
• 21 Wagner O F, Vierhapper H, Gasic S et al.. Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation.  Eur J Clin Invest. 1992;  22 277-282
• 22 Stewart D J, Levy R D, Cernacek P et al.. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?.  Ann Intern Med. 1991;  114 464-469
• 23 Nootens M, Kaufmann E, Rector T et al.. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels.  J Am Coll Cardiol. 1995;  26 1581-1585
• 24 Giaid A, Yanagisawa M, Langleben D et al.. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.  N Engl J Med. 1993;  328 1732-1739
• 25 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
• 26 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 27 Kawut S M, Taichman D B, Archer-Chicko C L et al.. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.  Chest. 2003;  123 344-350
• 28 McLaughlin V V, Sitbon O, Badesch D B et al.. Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
• 29 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
• 30 Sitbon O, Gressin V, Speich R et al.. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  170 1212-1217
• 31 Channick R N, Sitbon O, Barst R J et al.. Endothelin receptor antagonists in pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 62S-67S
• 32 Sitbon O, McLaughlin V, Badesch D B et al.. Comparison of two treatment strategies, first-line bosentan or epoprostenol, on survival in class III idiopathic pulmonary arterial hypertension [abstract].  Am J Respir Crit Care Med. 2004;  169 A442
• 33 Galie N, Seeger W, Naeije R et al.. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.  J Am Coll Cardiol. 2004;  43 (suppl 1, issue 12) 81S-88S
• 34 Barst R J, Rich S, Widlitz A et al.. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.  Chest. 2002;  121 1860-1868
• 35 Barst R J, Langleben D, Frost A et al.. Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
• 36 Langleben D, Hirsch A M, Shalit E et al.. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.  Chest. 2004;  126 1377-1381
• 37 Wilkins M R, Paul G A, Strange J W et al.. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study.  Am J Respir Crit Care Med. 2005;  171 1292-1297
• 38 Prins B A, Hu R M, Nazario B et al.. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells.  J Biol Chem. 1994;  269 11938-11944
• 39 Boulanger C, Luscher T F. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide.  J Clin Invest. 1990;  85 587-590
• 40 Humbert M, Barst R J, Robbins I M et al.. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.  Eur Respir J. 2004;  24 353-359
• 41 Hoeper M M, Taha N, Bekjarova A et al.. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids.  Eur Respir J. 2003;  22 330-334
• 42 Hoeper M M, Faulenbach C, Golpon H et al.. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
• 43 Wittke B, Burgess G, Ng T et al.. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil [abstract].  Proc Am Thorac Soc. 2005;  2 A200
• 44 Suleman N, Frost A E. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.  Chest. 2004;  126 808-815
• 45 Steiner M, Preston I, Klinger J et al.. Conversion from intravenous epoprostenol or subcutaneous treprostinil to oral bosentan in pulmonary arterial hypertension [abstract].  Proc Am Thorac Soc. 2005;  2 A203
• 46 Sitbon O, Humbert M, Ioos V et al.. Transition from intravenous epoprostenol to oral bosentan in pulmonary arterial hypertension [abstract].  Proc Am Thorac Soc. 2005;  2 A176
• 47 Palevsky H I, Taichman D B, Archer-Chicko C L. Weaning of continuously infused prostacyclin following addition of oral bosentan in patients with pulmonary arterial hypertension [abstract].  Proc Am Thorac Soc. 2005;  2 A172
• 48 Badesch D B, Abman S H, Ahearn G S et al.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126 35S-62S
• 49 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788